Company
Inspirna
Converting cancer to a manageable, chronic condition
Also known as Inspirna, Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Legal name
- Inspirna, Inc.
- inspirna.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Inspirna, Inc., is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need.
Funding snapshot
- Total raised
- $142MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Undisclosed, $50M2022-07-11
Funding rounds
- Series D Financing
- $50M2022-07-11, Company stated
- Round, 2022
- $55.1M2022-06-24, SEC form D sold, 20 investors
- Round, 2021
- $6M2021-02-12, SEC form D sold, 10 investors
- Round, 2018
- $39.8M2018-09-27, SEC form D sold, 10 investors
- Round, 2016
- $33M2016-06-03, SEC form D sold, 8 investors
- Round, 2015
- $8M2015-07-31, SEC form D sold, 33 investors
Products
- Other
- Abequolixron (RGX-104)
- Other
- Ompenaclid (RGX-202)
- Other
- RGX-019
Loading relationship preview